| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Squibb Institute for Medical Research, New Brunswick, New Jersey
Growth of mammary adenocarcinoma H2712 is inhibited by hydroxyurea. This compound was effective by daily, intermittent, or single s.c. injection. It was also effective when administered directly into the tumor.
Hydroxyurea is most efficacious when administered prior to the onset of rapid growth.
Simultaneous administration of hormones with antitumor activity in this system did not augment the effects of hydroxyurea.
Received 11/15/65. Accepted 5/24/66.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |